Study details
Enrolling now
Rimegepant Trial for Migraine Triggers
Medstar Health Research Institute
NCT IDNCT07301008ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
60
Study length
about 1.4 years
Ages
18+
Locations
1 site in VA
About this study
Researchers are testing whether Rimegepant can help prevent migraine attacks triggered by specific things like exercise, alcohol, or air travel. The trial will last about 509 days and involve adults with a history of migraine triggers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Rimegepant 75 MG
PhasePhase 4
DrugRimegepant 75 MG
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
rimegepant
Drug routes
oral (Disintegrating Oral Tablet)
Body systems
Neurology